[go: up one dir, main page]

AR122658A1 - Anticuerpos que se unen a cd3 - Google Patents

Anticuerpos que se unen a cd3

Info

Publication number
AR122658A1
AR122658A1 ARP210101662A ARP210101662A AR122658A1 AR 122658 A1 AR122658 A1 AR 122658A1 AR P210101662 A ARP210101662 A AR P210101662A AR P210101662 A ARP210101662 A AR P210101662A AR 122658 A1 AR122658 A1 AR 122658A1
Authority
AR
Argentina
Prior art keywords
antibodies
bind
methods
present
relates
Prior art date
Application number
ARP210101662A
Other languages
English (en)
Inventor
Gutierrez Cirlos Alejandro Carpy
Anne Freimoser-Grundschober
Thomas Hofer
Christian Klein
Ekkehard Moessner
Christiane Neumann
Pablo Umaa
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR122658A1 publication Critical patent/AR122658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en general a anticuerpos que se unen a CD3, que incluyen anticuerpos multiespecíficos, por ejemplo, para la activación de linfocitos T. Además, la presente invención se refiere a polinucleótidos que codifican dichos anticuerpos, y vectores y células huésped que comprenden dichos polinucleótidos. La invención se refiere adicionalmente a métodos para la producción de los anticuerpos y a métodos para usarlos en el tratamiento de una enfermedad.
ARP210101662A 2020-06-19 2021-06-17 Anticuerpos que se unen a cd3 AR122658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20180968 2020-06-19

Publications (1)

Publication Number Publication Date
AR122658A1 true AR122658A1 (es) 2022-09-28

Family

ID=71111260

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101662A AR122658A1 (es) 2020-06-19 2021-06-17 Anticuerpos que se unen a cd3

Country Status (18)

Country Link
US (1) US20220010015A1 (es)
EP (1) EP4168456A1 (es)
JP (1) JP2023530961A (es)
KR (1) KR20230025665A (es)
CN (1) CN115698084A (es)
AR (1) AR122658A1 (es)
AU (1) AU2021291407A1 (es)
BR (1) BR112022025574A2 (es)
CA (1) CA3176579A1 (es)
CL (1) CL2022003638A1 (es)
CO (1) CO2022017249A2 (es)
CR (1) CR20220628A (es)
IL (1) IL296089A (es)
MX (1) MX2022015204A (es)
PE (1) PE20230835A1 (es)
PH (1) PH12022500027A1 (es)
TW (1) TW202216766A (es)
WO (1) WO2021255142A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP6721590B2 (ja) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2024040127A2 (en) * 2022-08-16 2024-02-22 Northwestern University Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2025010538A1 (en) * 2023-07-07 2025-01-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gucy2c and uses thereof
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025196259A1 (en) 2024-03-22 2025-09-25 Hoffmann-La Roche Inc. Methods for producing molecules

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481656A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
RU2488597C2 (ru) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
HUE029257T2 (en) 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and their use
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RS56879B1 (sr) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
CN104125852B9 (zh) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 基于Fc‑受体的亲和色谱
CN114163530B (zh) 2012-04-20 2025-04-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
EP2961771B1 (en) * 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6744292B2 (ja) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
PE20170263A1 (es) 2014-08-04 2017-03-30 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
DK3221356T3 (da) * 2014-11-20 2020-11-02 Hoffmann La Roche T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
EP3368568B1 (en) 2015-10-29 2022-04-06 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
IL313608A (en) * 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
CN113621062B (zh) * 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体

Also Published As

Publication number Publication date
AU2021291407A1 (en) 2022-09-29
BR112022025574A2 (pt) 2023-01-03
WO2021255142A1 (en) 2021-12-23
CO2022017249A2 (es) 2023-02-16
PH12022500027A1 (en) 2024-03-25
MX2022015204A (es) 2023-01-05
TW202216766A (zh) 2022-05-01
PE20230835A1 (es) 2023-05-19
CN115698084A (zh) 2023-02-03
US20220010015A1 (en) 2022-01-13
CA3176579A1 (en) 2021-12-23
KR20230025665A (ko) 2023-02-22
EP4168456A1 (en) 2023-04-26
CL2022003638A1 (es) 2023-07-28
JP2023530961A (ja) 2023-07-20
CR20220628A (es) 2023-01-24
IL296089A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
AR122658A1 (es) Anticuerpos que se unen a cd3
CO2021008568A2 (es) Anticuerpos que se unen a cd3
CL2024000802A1 (es) Anticuerpos que se fijan a gprc5d
AR120857A1 (es) Anticuerpos que se unen a hla-a2 / mage-a4
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
AR119393A1 (es) Anticuerpos que se unen a nkg2d
UY39634A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
CO2023000057A2 (es) Anticuerpos que se unen a cd3 y cd19
CL2022000663A1 (es) Anticuerpos biespecificos contra ceacam5 y cd3
AR114001A1 (es) Anticuerpos que se unen a hla- a2 / wt1
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
AR122656A1 (es) Anticuerpos que se unen a cd3 / folr1
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
UY40770A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de éstas
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
PE20210634A1 (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
CO2024005918A2 (es) Anticuerpos de unión a cd30 y cd3
AR127887A1 (es) Anticuerpos que se unen a cd3 y plap
MX2023011273A (es) Anticuerpo dirigido a cd22 y cd79b.
AR125211A1 (es) Anticuerpos triespecíficos dirigidos a cd79b, cd20 y cd3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal